1. A phase II study of Zanubrutinib in combination with rituximab in patients with relapsed/refractory aggressive and indolent B-cell lymphoma. Issue 10 (24th August 2022) Authors: Zhang, Qingyuan; Tao, Rong; Li, Zhenyu; Guo, Haiyi; Ji, Meng; Zhang, Lu; Huang, Jane; Lina, Fu; Zhong, Jinhua; Zhou, Jianfeng Journal: Leukemia & lymphoma Issue: Volume 63:Issue 10(2022) Page Start: 2503 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A two‐part, single‐arm, multicentre, phase I study of zanubrutinib, a selective Bruton tyrosine kinase inhibitor, in Chinese patients with relapsed/refractory B‐cell malignancies. (5th April 2022) Authors: Song, Yuqin; Sun, Mingyuan; Qi, Junyuan; Xu, Wei; Zhou, Jianfeng; Li, Dengju; Li, Jianyong; Qiu, Lugui; Du, Chenmu; Guo, Haiyi; Huang, Jane; Tang, Zhiyu; Ou, Ying; Wu, Binghao; Yu, Yiling; Zhu, Jun Journal: British journal of haematology Issue: Volume 198:Number 1(2022) Page Start: 62 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Protective Effect of Vitamin C against Infancy Rat Corneal Injury Caused by Acute UVB Irradiation. (27th May 2020) Authors: Chen, Wei; Guo, Jianying; Guo, Haiyi; Kong, Xue; Bai, Jing; Long, Pan Other Names: Oliveira Mauro S. Academic Editor. Journal: BioMed research international Issue: Volume 2020(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗